A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

Non Small Cell Lung Cancer Clinical Trial

Official title:

A Multicenter, Open Label, Single Arm Phase 2 Study of AB-106 in the Treatment of Locally Advanced and Metastatic NSCLC

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04395677
• Other study ID #: AB-106-C203
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: July 7, 2020
• Est. completion date: December 31, 2025

Study information

• Verified date: October 2023
• Source: AnHeart Therapeutics Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC.

Description:

This is a Phase II, multicenter, single-arm, open label study of AB-106 in the Chinese patients with advanced NSCLC harboring ROS1 fusion gene.The study will be divided into two stages. First stage (Stage I) is to determine the clinical optimal dose of AB-106, which will be evaluated at two dose levels (400 mg QD and 600mg QD), and the safety, tolerability and pharmacokinetics of AB-106 will be evaluated at the same time; Second stage (Stage II) is to evaluate the efficacy and safety of AB-106 at the clinical optimal dose determined from Stage I. It is expected that 6 patients with advanced NSCLC harboring ROS1 fusion will be enrolled in the first stage. About 167 patients with ROS1 fusion will be enrolled in the second stage and divided into two treatment cohorts (Cohort A & Cohort B). It is planned to enroll about 106 ROS1-TKI treatment naïve patients in Cohort A and about 67 crizotinib pre-treated patients in Cohort B. AB-106 will be administered 600mg once daily in 21-day cycles. Patients will continue with the study treatment until progression of disease as determined by the investigator. The tumor response evaluation will be conducted in every 6 weeks in the first 8 cycles, and then every 12 weeks until progression of disease as determined by the investigator. The long-term survival follow up will be conducted every 12 weeks.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 173
• Est. completion date: December 31, 2025
• Est. primary completion date: December 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patients must meet all of the following criteria to be eligible for enrollment into the study:

1. = 18 years of age

2. Histologically or cytologically confirmed locally advanced or metastatic NSCLC

3. Positivity of ROS1 fusion is determined by the local qualified laboratories by using the FISH, RT-PCR or NGS assay, and the subject must provide archival tumor tissue sample for the confirmation by a sponsor-designated central laboratory

4. The subject is either TKI treatment naïve(Cohort A), or has disease progression following the treatment of crizotinib (Cohort B)

5. The patient with brain metastases is either asymptomatic, or neurologically stable for at least 2 weeks prior to study entry

6. Prior therapies (including chemotherapies [less than 3 lines of regimen], radiotherapy [except for palliative], or surgery) should be completed at least 2 weeks prior to study entry. The palliative radiotherapy (=10 times) should be completed within 48 hours prior to study entry. Any acute toxic effect must be resolved to CTCAE Grade =1 except for alopecia

7. At least one measurable target tumor lesion (as accessed by RECIST v1.1) that has not been irradiated

8. ECOG Performance Status: 0 or 1

9. Patient with a life expectancy = 3 months based on the judgement of investigators

Adequate organ functions defined by the following criteria:

• Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) =2.5 x ULN; or =5 x ULN, if there is liver metastases involvement;

• Total serum bilirubin =1.5 x ULN;

• Absolute neutrophil count(ANC) =1500/µL;

• Platelet count=100,000/µL;

• Hemoglobin=8.0 g/dL;

• Serum creatinine =2 x ULN. 11. Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of the pertinent aspect of the study 12. Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures 13. Male and female patients of childbearing potential must agree to sue effective methods of contraception throughout the study and for 90 days after the last dose of study medication.

Exclusion Criteria:

Patient presenting with any of the following criteria will not be included in the study:

1. Current participation in other therapeutic investigational studies

2. Previous participation in the treatment or clinical trials of other ROS1-TKIs (except for crizotinib)

3. Previous participation in the treatment and clinical trials of ALK or NTRK fusion gene targeted therapies.

4. Spinal cord compression unless the patient demonstrates good pain control and stabilization or recovery of neurological function, carcinomatous meningitis or leptomeningeal disease

5. Patients with interstitial fibrosis or interstitial lung disease

6. Any one of the following currently or in the previous 3 months: myocardial infarction, severe/unstable angina, coronary/ peripheral artery bypass graft, congestive heart failure or cerebrovascular accident including transient ischemic attack

7. Ongoing cardiac dysrhythmias of NCI CTCAE (v5.0) Grade=2, uncontrolled atrial fibrillation of any grade, or QTc interval>470 microsec

8. Pregnancy or breastfeeding

9. Current use of food or drugs that are known strong CYP3A inhibitors, including (but not limited to) atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, grapefruit or grapefruit juice.

10. Current use of drugs that are known strong CYP3A4 inducers, including (but not limited to) carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St John's Wort

11. Current use of drugs that are known CYP3A4 substrates with narrow therapeutic indices, including (but not limited to) dihydroergotamine, ergotamine, pimozide, astemizole, cisapride, and terfenadine.

12. Current use of drugs that are known to induce QTc prolongation

13. Systematic treatment with anti-cancer therapy, including any Traditional Chinese Medicine (TCM)with anti-tumor effect indicated in the prescription information.

14. Evidence of active malignancy (other than current NSCLC, non-melanoma skin cancer, in situ cervical cancer, and presumed cured prostate cancer) within the last 3 years

15. Clinically active viral disease with positivity of serum HIV, HBV, HCV, RPR testing

16. Difficult to swallow which may significantly impact drug absorption

17. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation in the judgement of investigator and sponsor

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Non Small Cell Lung Cancer

Intervention

Drug:
• AB-106
Stage 1: 400mg QD for 3 patients and 600mg QD for 3 patients Stage 2: 600mg QD

Locations

Country	Name	City	State
China	Shanghai Pulmonary Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
AnHeart Therapeutics Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Best overall response (BOR) by IRC	Best overall response (BOR) based on independent radiology review by Independent Review Committee(IRC) according to RECIST 1.1	6 months
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	25 months
Secondary	Rate of ECG QT Interval prolongation patients in all patients	After the medicine, the number of patients with ECG QT Interval and the rate of patients with clinical significant	25 months
Secondary	Maximum Plasma Concentration [Cmax]	The Cmax of Cycle1Day1 and Cycle1Day15 will be assessed, (each cycle is 21 days)	Day 1 to Cycle1Day15
Secondary	Area under the curve from time zero to t (dose interval t is 24 h in this study) [AUCt]	The AUCt of Cycle1Day1 and Cycle1Day15 will be assessed, (each cycle is 21 days)	Day 1 to Cycle1Day15
Secondary	Average plasma concentration at steady state over dosing interval [Cav]	The Cav of Cycle1Day1 and Cycle1Day15 will be assessed, (each cycle is 21 days)	Day 1 to Cycle1Day15
Secondary	Trough plasma concentration [Ctrough]	The Cthrough of Cycle1Day1 and Cycle1Day15 will be assessed, (each cycle is 21 days)	Day 1 to Cycle1Day15
Secondary	Time to reach maximum plasma concentration [Tmax]	The Tmax of Cycle1Day1 and Cycle1Day15 will be assessed, (each cycle is 21 days)	Day 1 to Cycle1Day15
Secondary	Duration of Response(DOR)	Duration of Response(DOR) based on independent radiology review by Independent Review Committee(IRC) and investigator according to RECIST 1.1	25 months
Secondary	Time to Response(TTR)	Time to Response(TTR) based on independent radiology review by Independent Review Committee(IRC) and investigator according to RECIST 1.1	6 months
Secondary	Time to Progress(TTP)	Time to Progress(TTP) based on independent radiology review by Independent Review Committee(IRC) and investigator according to RECIST 1.1; OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.	25 months
Secondary	Progression free Survival(PFS)	Progression free Survival(PFS) based on independent radiology review by Independent Review Committee(IRC) and investigator according to RECIST 1.1	25 months
Secondary	Intracranial best overall response (IBOR)	Intracranial Best overall response (BOR) based on independent radiology review by Independent Review Committee(IRC) and Investigator according to RANO for intracranial lesion	25 months
Secondary	Duration of intracranial response (IDOR)	Duration of intracranial response (IDOR) based on independent radiology review by Independent Review Committee(IRC) and Investigator according to RANO for intracranial lesion	25 months
Secondary	Overall Survival(OS)	OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.	51 months